FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019420147> ?p ?o ?g. }

• W2019420147 abstract "To understand T cell immune surveillance in pancreatic ductal adenocarcinoma (PDA), our laboratory has studied the KPC genetically engineered mouse model of this disease. Unexpectedly, we found that effector T cells are scarce in both preinvasive and invasive lesions, whereas immune suppressive cells, including tumor-associated macrophages, immature myeloid cells, and regulatory T cells, are prominent at even the earliest stages of neoplasia and persist through invasive cancer. These findings are consistent with the immune infiltrate observed in human PDA in which a marked macrophage and myeloid cell infiltration is associated with few effector T cells. Because suppressive cells of the immune system appear early during pancreatic tumorigenesis, we hypothesize that the absence of effector T cell immune surveillance in PDA may be more consistent with “immunological ignorance” than “immunoediting.” In this scenario, PDA cells may be particularly sensitive to T cell killing because of a lack of T cell selective pressure in vivo. To explore this hypothesis, we have evaluated a CD40 agonist antibody for its ability to reverse immune suppression and activate the immune system. In patients with metastatic pancreatic cancer, we found that a CD40 agonist antibody in combination with gemcitabine led to major tumor regressions in a fraction of patients. To understand the mechanism of this effect, we studied two murine models of PDA: (1) a transplant model in which PDA tumor cell lines derived from KPC mice are implanted into syngeneic littermates and (2) the spontaneous KPC model of PDA. We have found that PDA tumors implanted subcutaneously into non-KPC mice grow readily, but upon treatment with an agonist CD40 mAb and gemcitabine, established PDA tumors undergo complete regression associated with a robust T cell infiltrate. Systemic T cell depletion abrogated this regression indicating a T-cell dependent effect. In contrast, when KPC mice bearing spontaneously arising PDA tumors were treated with an agonist CD40 mAb and gemcitabine, a fraction of tumors regressed but in the absence of tumor-infiltrating T cells (mirroring the clinical trial). To determine whether T cells in KPC animals were globally tolerized, KPC mice bearing a spontaneous tumor were challenged with PDA cells subcutaneously. As seen in non-KPC mice, subcutaneously implanted tumors grew exponentially and were found to lack infiltrating T cells. However, when treated with an agonist CD40 mAb and gemcitabine, these implanted tumors exhibited a marked T-cell infiltration leading to regression, suggesting that effector T cells can target PDA in the KPC model. Moreover, treatment of KPC mice bearing both implanted and subcutaneously arising tumors produced an impressive influx of T cells into the primary pancreatic tumors of KPC mice, a finding that was not observed when KPC mice were activated with CD40 mAb and gemcitabine in the absence of the PDA subcutaneous implant. Thus, tumor-reactive T cells in KPC mice are not clonally deleted or globally tolerant to PDA. These data suggest that elements of the tumor microenvironment may mediate local immune suppression that can be overcome by immune priming outside the tumor microenvironment. Our findings have important implications for the design of novel immunotherapy trials in pancreatic cancer, and highlight the opportunity to develop vaccines and other T cell therapies for this disease. Citation Format: Gregory L. Beatty, Rafael Winograd, Rebecca A. Evans, Robert H. Vonderheide. Immune surveillance and CD40 therapy of pancreatic cancer in mice and humans. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Progress and Challenges; Jun 18-21, 2012; Lake Tahoe, NV. Philadelphia (PA): AACR; Cancer Res 2012;72(12 Suppl):Abstract nr IA9." @default.
• W2019420147 created "2016-06-24" @default.
• W2019420147 creator A5011736012 @default.
• W2019420147 creator A5014753848 @default.
• W2019420147 creator A5040750947 @default.
• W2019420147 creator A5051182961 @default.
• W2019420147 date "2012-07-15" @default.
• W2019420147 modified "2023-09-23" @default.
• W2019420147 title "Abstract IA9: Immune surveillance and CD40 therapy of pancreatic cancer in mice and humans." @default.
• W2019420147 doi "https://doi.org/10.1158/1538-7445.panca2012-ia9" @default.
• W2019420147 hasPublicationYear "2012" @default.
• W2019420147 type Work @default.
• W2019420147 sameAs 2019420147 @default.
• W2019420147 citedByCount "0" @default.
• W2019420147 crossrefType "proceedings-article" @default.
• W2019420147 hasAuthorship W2019420147A5011736012 @default.
• W2019420147 hasAuthorship W2019420147A5014753848 @default.
• W2019420147 hasAuthorship W2019420147A5040750947 @default.
• W2019420147 hasAuthorship W2019420147A5051182961 @default.
• W2019420147 hasConcept C121608353 @default.
• W2019420147 hasConcept C126322002 @default.
• W2019420147 hasConcept C154317977 @default.
• W2019420147 hasConcept C159654299 @default.
• W2019420147 hasConcept C202751555 @default.
• W2019420147 hasConcept C203014093 @default.
• W2019420147 hasConcept C2777701055 @default.
• W2019420147 hasConcept C2779282312 @default.
• W2019420147 hasConcept C2779727006 @default.
• W2019420147 hasConcept C2780210213 @default.
• W2019420147 hasConcept C2780480104 @default.
• W2019420147 hasConcept C39347974 @default.
• W2019420147 hasConcept C502942594 @default.
• W2019420147 hasConcept C55493867 @default.
• W2019420147 hasConcept C71924100 @default.
• W2019420147 hasConcept C86803240 @default.
• W2019420147 hasConcept C8891405 @default.
• W2019420147 hasConceptScore W2019420147C121608353 @default.
• W2019420147 hasConceptScore W2019420147C126322002 @default.
• W2019420147 hasConceptScore W2019420147C154317977 @default.
• W2019420147 hasConceptScore W2019420147C159654299 @default.
• W2019420147 hasConceptScore W2019420147C202751555 @default.
• W2019420147 hasConceptScore W2019420147C203014093 @default.
• W2019420147 hasConceptScore W2019420147C2777701055 @default.
• W2019420147 hasConceptScore W2019420147C2779282312 @default.
• W2019420147 hasConceptScore W2019420147C2779727006 @default.
• W2019420147 hasConceptScore W2019420147C2780210213 @default.
• W2019420147 hasConceptScore W2019420147C2780480104 @default.
• W2019420147 hasConceptScore W2019420147C39347974 @default.
• W2019420147 hasConceptScore W2019420147C502942594 @default.
• W2019420147 hasConceptScore W2019420147C55493867 @default.
• W2019420147 hasConceptScore W2019420147C71924100 @default.
• W2019420147 hasConceptScore W2019420147C86803240 @default.
• W2019420147 hasConceptScore W2019420147C8891405 @default.
• W2019420147 hasLocation W20194201471 @default.
• W2019420147 hasOpenAccess W2019420147 @default.
• W2019420147 hasPrimaryLocation W20194201471 @default.
• W2019420147 hasRelatedWork W1259279500 @default.
• W2019420147 hasRelatedWork W1506647723 @default.
• W2019420147 hasRelatedWork W1974620879 @default.
• W2019420147 hasRelatedWork W2003298559 @default.
• W2019420147 hasRelatedWork W2014896047 @default.
• W2019420147 hasRelatedWork W2093683818 @default.
• W2019420147 hasRelatedWork W2116495352 @default.
• W2019420147 hasRelatedWork W2395000660 @default.
• W2019420147 hasRelatedWork W2476540671 @default.
• W2019420147 hasRelatedWork W2573678725 @default.
• W2019420147 hasRelatedWork W2797866384 @default.
• W2019420147 hasRelatedWork W2887004316 @default.
• W2019420147 hasRelatedWork W2896143580 @default.
• W2019420147 hasRelatedWork W2911285649 @default.
• W2019420147 hasRelatedWork W2912621681 @default.
• W2019420147 hasRelatedWork W2956040513 @default.
• W2019420147 hasRelatedWork W2956922957 @default.
• W2019420147 hasRelatedWork W2974957158 @default.
• W2019420147 hasRelatedWork W3011773444 @default.
• W2019420147 hasRelatedWork W3096664027 @default.
• W2019420147 isParatext "false" @default.
• W2019420147 isRetracted "false" @default.
• W2019420147 magId "2019420147" @default.
• W2019420147 workType "article" @default.